Q-Linea AB Announces Reverse Share Split

In a strategic move to consolidate its share structure, Q-Linea AB, a prominent player in the health care equipment and supplies sector, has announced a reverse share split. This decision, ratified at the company’s annual general meeting on June 26, 2025, aims to streamline its share distribution by combining 1,000 existing shares into one new share. The reverse split, set at a ratio of 1:1,000, is scheduled to take effect on July 14, 2025.

The board of directors has determined that the record date for this reverse split will be July 15, 2025. Consequently, trading in Q-Linea’s shares will conclude on July 13, 2025, with the adjusted share price reflecting the reverse split from July 14, 2025. This adjustment is expected to reduce the total number of shares in circulation, thereby potentially enhancing the stock’s market perception and liquidity.

Q-Linea AB, headquartered in Uppsala, Sweden, specializes in developing diagnostic instruments and systems for infectious diseases. Despite its focus on the Swedish market, the company’s strategic financial maneuvers, such as this reverse share split, underscore its commitment to maintaining a robust and efficient capital structure.

As of July 6, 2025, Q-Linea’s share price stood at SEK 0.0641, a significant drop from its 52-week high of SEK 4.69 on July 9, 2024. The reverse share split is anticipated to adjust the share price accordingly, reflecting the new share structure.

Shareholders are advised that the reverse split will be executed automatically through Euroclear Sweden AB, requiring no action on their part. This seamless transition is designed to ensure minimal disruption while aligning the company’s share structure with its long-term strategic goals.

For further details, stakeholders can refer to Q-Linea’s official communications or visit their website at www.qlinea.com . As the company continues to navigate the dynamic health care landscape, this reverse share split marks a pivotal step in its ongoing efforts to optimize its financial framework and enhance shareholder value.